Clinical studies with the anti-VEGF monoclonal antibody, bevacizumab, have shown that targeting human VEGF-A is an effective treatment strategy in patients with metastatic colorectal cancer (mCRC) [4, 5], advanced non-small cell lung cancer (NSCLC) [6], metastatic renal cancer [7, 8] and glioblastoma multiforme [9]. Here, VEGFA is linked to glioblastoma.